Age-Related Macular Degeneration, Branch Retinal Vein Occlusion with Macular Edema, Central Retinal Vein Occlusion with Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy
Conditions
Brief summary
The objective of the study is to assess the ocular safety of the FYB203 pre-filled syringe in terms of preparation and administration by Retina Specialists in the clinical setting.
Interventions
DRUGFYB203 2 mg (0.05 mL of 40 mg/mL)
IVT administration of FYB203 in a PFS
Sponsors
Formycon AG
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Study eye deemed to be indicated for aflibercept IVT injection therapy at the discretion of the Investigator. 2. Written and signed informed consent form (ICF) obtained before any study-related procedures. 3. Had a confirmed diagnosis in one or both eyes of neovascular (wet) AMD or macular edema following RVO or DME or DR. 4. Qualified for treatment with aflibercept according to the United States Prescribing Information. 5. Aged ≥18 years at the time of signing ICF. 6. If a subject was already on an aflibercept regimen, timing of study participation was correlated with the regimen. 7. Male study subject (if his female spouse/partner was of childbearing potential) must have confirmed that he was using two acceptable methods for contraception (one of which must be a barrier method) starting at signing ICF and throughout the clinical study period and for 3 months after IP administration. Male study subject must have agreed to inform his partner of participation in the study and the need to avoid pregnancy. Surgically sterilized and non sexually active male subjects did not require any additional use of contraception. 8. Male study subject agreed not to donate sperm starting from screening and throughout the clinical study period and for 3 months after IP administration. 9. Female study subject was categorized by at least one of the following: * Not a woman of childbearing potential as described in Appendix 3 of the study protocol prior to signing ICF, or * Surgically sterile or had undergone a hysterectomy as categorized in Appendix 3 of the study protocol at least 1 month prior to signing ICF, or * Was using a highly effective contraception. All females of childbearing potential were required to use highly effective contraception (as described in Appendix 3 of the study protocol) starting at signing ICF and throughout the clinical study period and for 3 months after IP administration. 10. Female study subject must not be lactating and must not be breastfeeding at screening until 3 months after IP administration. 11. Female study subject must not donate ova starting at signing ICF and throughout the clinical study period and for 3 months after IP administration.
Exclusion criteria
1. Had received IVT injection in the study eye within 3 months prior to Day 1 with any anti vascular endothelial growth factor therapy other than aflibercept products (ege.g., Eylea). 2. Intraocular corticosteroid administration in the study eye within 30 days prior to Day 1. 3. Had fever or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non cutaneous) infection within 1 week prior to Day 1. 4. History or evidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection in the last month prior to signing ICF or had been in confirmed contact with SARS-CoV-2 positive subjects in the last 2 weeks before dosing.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence and occurrence of ocular and non-ocular Adverse Events (AEs) and Serious Adverse Events (SAEs) occurring after IVT injection | 2 days | To assess the ocular safety of the FYB203 PFS in terms of preparation and administration by Retina Specialists. |
Countries
United States
Outcome results
None listed